FDA Orange Book · active-ingredient family
Lonafarnib
Lonafarnib is approved in 1 FDA application, with therapeutic-equivalence codes, listed patents, and marketing exclusivity from the FDA Orange Book.
Reference-listed drug:ZOKINVY · NDA 213969
1
Brand (NDA)
0
Generics (ANDA)
1
Listed patents
2
Exclusivity periods
Brand (NDA) products · capsule
| Product | Applicant | Application | TE | Approved | |
|---|---|---|---|---|---|
| ZOKINVYRLD×2 | SENTYNL THERAPS INC | NDA 213969 | — | Nov 20, 2020 |
Marketing exclusivity (2)
- ODE-324Orphan-drug exclusivity (7 years)
Nov 20, 2027
in 1 yr 5 mo
- ODE-324Orphan-drug exclusivity (7 years)
Nov 20, 2027
in 1 yr 5 mo
Listed patents (1)
| Patent | Expires | In | Type |
|---|---|---|---|
| 7838531 | Jul 26, 2029 | in 3 yr 2 mo | U-3070 |
Lonafarnib — frequently asked questions
Generics, reference-listed drug, patents, and exclusivity for this active ingredient, from the FDA Orange Book.

